Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4186 to 4200 of 8898 results

  1. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    Page 1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at high risk Published

  2. Medicines associated with dependence or withdrawal symptoms. Patient decision aid full version on should I stop my benzodiazepine or z-drug?

    Should I stop my benzodiazepine or z-drug? This decision aid can help if you have been prescribed a benzodiazepine or z-drug for anxiety or sleeping...

  3. Type 2 diabetes in adults. Patient decision aid on type 2 diabetes: agreeing my blood glucose (HbA1c) target

    1 Type 2 diabetes: agreeing my blood glucose (HbA1c) target Patient decision aid c NICE 2022. All rights reserved. Subject to Notice of rights. Last...

  4. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  5. Good practice guidance – Integrated process statement (PMG12)

    This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

  6. Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)

    This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs

  7. Evidence summaries: new medicines – Interim process statement (PMG1)

    This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs

  8. Methods for the development of NICE public health guidance (third edition) (PMG4)

    This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance

  9. Selecting and prioritising quality standard topics

    Each year we work with NHSE and the DHSC to prioritise topics for development.

  10. Notify an interventional procedure

    Tell us about an interventional procedure you think should be assessed by NICE.

  11. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  12. About evidence summaries

    Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.

  13. Get involved with HealthTech guidance

    We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.

  14. Technology appraisal and highly specialised technologies appeals

    Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.

  15. About highly specialised technologies guidance

    Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.